Poole Chris D, Bannister Christian A, Andreasen Jakob Nørgaard, Andersen Jens Strodl, Currie Craig J
Cochrane Institute of Primary Care and Public Health, Cardiff University, Cardiff, Wales, UK.
Health Qual Life Outcomes. 2014 Jun 13;12:99. doi: 10.1186/1477-7525-12-99.
Grass allergen immunotherapy (AIT) reduces symptom severity in seasonal allergic rhinoconjunctivitis (ARC) but its impact on general health-related utility has not been characterised for the purposes of economic evaluation. The aim of this study was to model the preferred measure of utility, EQ-5D index, from symptom severity and estimate incremental quality adjusted life years (QALYs) associated with SQ-standardised grass immunotherapy tablet (GRAZAX®, 75,000 SQ-T/2,800 BAU, ALK, Denmark).
Data were analysed from five consecutive pollen seasons in a randomised placebo controlled trial of GRAZAX®. Binomial and Gaussian mixed effects modelling related weekly EQ-5D index score to daily symptom and medication scores (DSS & DMS respectively). In turn, daily EQ-5D index was estimated from ARC symptoms and medication use.
DSS and DMS were the principal predictors of 'perfect' health (EQ-5D = 1.000; binomial) and 'imperfect' health (EQ-5D < 1.000; Gaussian). Each unit increase in DSS and DMS reduced the odds of 'perfect' health (EQ-5D = 1.000) by 27% and 16% respectively, and reduced 'imperfect' health by 0.17 and 0.13, respectively. Gender remained the only other significant main fixed effect (Male odds ratio [OR] = 1.82). Incremental estimated EQ-5D index utility for GRAZAX® was observed from day -30 to day +70 of the pooled pollen season; mean daily utility for GRAZAX® = 0.938 units (95%CI 0.932-0.943) vs. 0.914 (0.907-0.921) for placebo, an incremental difference of 0.0238 (p < 0.001). This translates into an incremental 0.0324 Quality Adjusted Life Years over the five year study period.
ARC symptoms and medication use are the main predictors of EQ-5D index. The incremental QALYs observed for GRAZAX® may not fully describe the health benefits of this treatment, suggesting that economic modelling may be conservative.
草类过敏原免疫疗法(AIT)可减轻季节性变应性鼻结膜炎(ARC)的症状严重程度,但就经济评估而言,其对一般健康相关效用的影响尚未得到明确描述。本研究的目的是根据症状严重程度对效用的首选衡量指标EQ-5D指数进行建模,并估计与SQ标准化草免疫疗法片剂(GRAZAX®,75,000 SQ-T/2,800 BAU,ALK,丹麦)相关的增量质量调整生命年(QALY)。
对GRAZAX®的一项随机安慰剂对照试验中连续五个花粉季节的数据进行分析。二项式和高斯混合效应模型将每周EQ-5D指数得分与每日症状和药物得分(分别为DSS和DMS)相关联。反过来,根据ARC症状和药物使用情况估计每日EQ-5D指数。
DSS和DMS是“完美”健康(EQ-5D = 1.000;二项式)和“不完美”健康(EQ-5D < 1.000;高斯)的主要预测因素。DSS和DMS每增加一个单位,“完美”健康(EQ-5D = 1.000)的几率分别降低27%和16%,“不完美”健康分别降低0.17和0.13。性别仍然是唯一其他显著的主要固定效应(男性优势比[OR] = 1.82)。在合并花粉季节的第-30天至第+70天观察到GRAZAX®的增量估计EQ-5D指数效用;GRAZAX®的平均每日效用 = 0.938单位(95%CI 0.932 - 0.943),而安慰剂为0.914(0.907 - 0.921),增量差异为0.0238(p < 0.001)。这相当于在五年研究期间增加了0.0324个质量调整生命年。
ARC症状和药物使用是EQ-5D指数的主要预测因素。观察到的GRAZAX®的增量QALY可能无法完全描述这种治疗的健康益处,这表明经济建模可能较为保守。